Effects of Chuanhuang Formula combined with prostaglandin E1 in treating patients of chronic kidney disease complicated with acute kidney injury and its influence on NLRP3

GONG Xuezhong; YE Zi; XU Xiangnan; CHEN Ling; XU Yingru; YUAN Daochuan; WANG Danjun; LIU Jianlian; LI Tonglu

doi:10.16306/j.1008-861x.2021.06.002

您当前的位置：

首页 >

文章列表页 >

Effects of Chuanhuang Formula combined with prostaglandin E1 in treating patients of chronic kidney disease complicated with acute kidney injury and its influence on NLRP3

Clinical Research | 更新时间：2022-09-09

- Effects of Chuanhuang Formula combined with prostaglandin E1 in treating patients of chronic kidney disease complicated with acute kidney injury and its influence on NLRP3
- Academic Journal of Shanghai University of Traditional Chinese Medicine Vol. 35, Issue 6, Pages: 12-16(2021)
- 作者机构：
  
  1.上海中医药大学附属市中医医院肾内科（上海　200071）
  2.上海市青浦区徐泾镇社区卫生服务中心（上海　201702）
  3.上海市第一人民医院胸外科（上海　200080）
- 作者简介：
- 基金信息：
- DOI：10.16306/j.1008-861x.2021.06.002
  CLC：
扫描看全文
GONG Xuezhong, YE Zi, XU Xiangnan, et al. Effects of Chuanhuang Formula combined with prostaglandin E1 in treating patients of chronic kidney disease complicated with acute kidney injury and its influence on NLRP3. [J]. Academic Journal of Shanghai University of Traditional Chinese Medicine 35(6):12-16(2021)
DOI：

GONG Xuezhong, YE Zi, XU Xiangnan, et al. Effects of Chuanhuang Formula combined with prostaglandin E1 in treating patients of chronic kidney disease complicated with acute kidney injury and its influence on NLRP3. [J]. Academic Journal of Shanghai University of Traditional Chinese Medicine 35(6):12-16(2021) DOI： 10.16306/j.1008-861x.2021.06.002.

摘要

目的：,2,观察川黄方联合前列腺素E1方案治疗慢性肾脏病（CKD）合并急性肾损伤（AKI）患者的临床疗效，并从Nod样受体蛋白3（NLRP3）炎症小体角度探讨其疗效机制。,方法：,2,将103例符合纳入标准的CKD合并AKI（A on C）患者随机分为治疗组52例和对照组51例。所有患者均给予西医基础治疗，对照组患者在基础治疗同时给予前列腺素E1注射液静脉滴注，治疗组患者在对照组基础上给予川黄方口服加灌肠治疗，两组疗程均为2周。评估两组患者的临床疗效及中医证候积分；治疗前后检测所有患者的血肌酐（Scr）、血尿素氮（BUN）、血尿酸（UA）、肾小球滤过率估计值（eGFR）、24 h尿蛋白定量（24 h UPro）及血清NLRP3、白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、超敏C反应蛋白（hs-CRP）的水平。,结果：,2,①临床疗效：治疗后，治疗组患者的临床总有效率为73.1%，对照组为33.3%，治疗组的疗效优于对照组（,P,<,0.01）。②中医证候积分：治疗后，两组患者的中医证候总积分较治疗前均显著降低（,P,<,0.01），且治疗组患者的总积分低于对照组（,P,<,0.05）。③肾功能指标：治疗后，两组患者的Scr、UA水平较治疗前均降低（,P,<,0.05，,P,<,0.01），eGFR水平均升高（,P,<,0.05，,P,<,0.01），治疗组患者的BUN水平较治疗前亦降低（,P,<,0.01），且治疗组患者的Scr、BUN、UA水平低于对照组（,P,<,0.05），eGFR水平高于对照组（,P,<,0.05）。④24 h UPro：治疗后，治疗组患者的24 h UPro水平较治疗前明显降低（,P,<,0.01），且明显低于对照组（,P,<,0.05）。⑤炎症指标：治疗后，两组患者的IL-6、TNF-α、hs-CRP水平较治疗前均降低（,P,<,0.05，,P,<,0.01），治疗组患者的NLRP3水平较治疗前亦降低（,P,<,0.01），且治疗组患者的IL-6、TNF-α及NLRP3水平低于对照组（,P,<,0.05）。,结论：,2,与单用前列腺素E1治疗相比，川黄方联合前列腺素E1治疗能更好地减轻A on C患者的肾脏损伤，其疗效机制可能与调节患者的炎症状态有关。

Abstract

Objective:,2,To observe the clinical efficacy of Chuanhuang Formula combined with prostaglandin E1 regimen in treating patients of chronic kidney disease(CKD) complicated with acute kidney injury(AKI), and explore its therapeutic mechanisms from the perspective of Nod-like receptor protein 3(NLRP3) inflammasome.,Methods:,2,A total of 103 patients of CKD complicated with AKI(A on C) who met the inclusion criteria were randomly divided into the treatment group(52 cases) and control group(51 cases) .All patients were treated with basic therapy of western medicine.The patients in the control group were intravenously treated with prostaglandin E1 injection based on the basic treatment, and the patients in the treatment group were treated with Chuanhuang Formula by oral administration and coloclysis based on the treatment for the control group. The treatment course of both groups was 2 weeks.The clinical efficacy and the score of Chinese medical syndrome in both groups were evaluated. Before and after treatment, the levels of serum creatinine(Scr), blood urea nitrogen(BUN), blood uric acid(UA), estimated glomerular filtration rate(eGFR), 24-hour urinary protein(24 h UPro) and serum NLRP3, interleukin-6(IL-6), tumor necrosis factor-α(TNF-α) and high sensitive C-reactive protein(hs-CRP) were detected.,Results:,2,①Clinical efficacy: After treatment, the total clinical effective rates of the treatment group and the control group were 73.1% and 33.3% respectively, and the efficacy of the treatment group was better than that of the control group(,P,<,0.01) .②Chinese medical syndrome score: After treatment, the total score of Chinese medical syndrome in both groups was significantly decreased compared with that before treatment(,P,<,0.01), and the total score of the treatment group was lower than that of the control group(,P,<,0.05) .③Indexes of renal function: After treatment, the levels of Scr and UA in both groups were decreased compared with those before treatment(,P,<,0.05,P,<,0.01), the level of eGFR was increased(,P,<,0.05,P,<,0.01), the level of BUN in the treatment group was also decreased compared with that before treatment(,P,<,0.01), and the levels of Scr, BUN and UA in the treatment group were lower than those in the control group(,P,<,0.05), the level of eGFR in the treatment group was higher than that in the control group(,P,<,0.05) .④24 h UPro: After treatment, the level of 24 h UPro in the treatment group was significantly decreased compared with that before treatment(,P,<,0.01), and was significantly lower than that in the control group(,P,<,0.05) .⑤Inflammatory indexes: After treatment, the levels of IL-6, TNF-α and hs-CRP in both groups were decreased compared with those before treatment(,P,<,0.05,P,<,0.01), the level of NLRP3 in the treatment group was also decreased compared with that before treatment(,P,<,0.01), and the levels of IL-6, TNF-α and NLRP3 in the treatment group were lower than those in the control group(,P,<,0.05) .,Conclusion:,2,Compared with prostaglandin E1 alone, Chuanhuang Formula combined with prostaglandin E1 can better alleviate the kidney injury in patients of A on C, and its therapeutic mechanism may be related to the regulation of inflammatory status.

关键词

慢性肾脏病急性肾损伤川黄方前列腺素E1NLRP3炎症小体

Keywords

chronic kidney diseaseacute kidney injuryChuanhuang Formulaprostaglandin E1NLRP3 inflammasome

references

GEWIN L S.Transforming Growth Factor-β in the Acute Kidney Injury to Chronic Kidney Disease Transition[J].Nephron，2019，143(3)：154-157.

龚学忠，段怡茹，王怡，等.川黄方对2～4期慢性肾脏病合并急性肾损伤患者肾功能及氧化应激的影响[J].上海中医药大学学报，2020，34(1)：11-16.

YANG L，XING G，WANG L, et al.Acute kidney injury in China: across-sectional survey[J].Lancet，2015，386(10002)：1465-1471.

XU X，NIE S，LIU Z, et al.Epidemiology and Clinical Correlates of AKI in Chinese Hospitalized Adults[J].Clin J Am Soc Nephrol，2015，10(9)：1510-1518.

曹杰，赵宇亮，付平.急性肾损伤流行病学的新进展[J].中国循证医学杂志，2019，19(6)：631-634.

龚学忠，汤晓春，王骞，等.川黄方联合前列腺素E1对60例2～4期CKD合并AKI患者的疗效观察[J].中国中西医结合肾病杂志，2014，15(9)：784-787.

龚学忠，汤晓春，王骞，等.解毒化瘀法联合前列腺素E1治疗慢性肾脏疾病2～4期合并急性肾损伤的临床研究[J].临床肾脏病杂志，2014，14(11)：666-669.

LEVEY A S，CORESH J.Chronic kidney disease[J].Lancet，2012，379(9811)：165-180.

KHWAJA A.KDIGO clinical practice guidelines for acute kidney injury[J].Nephron Clin Pract，2012，120(4)：c179-c184.

上海市肾内科临床质量控制中心.上海市肾内科质控手册[M].上海：上海科学技术出版社, 2014:1297.

郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社, 2002:156-161.

中华中医药学会肾病分会.慢性肾衰竭的诊断、辨证分型及疗效评定（试行方案）[J].上海中医药杂志，2006，40(8)：8-9.

SETHI S K，CHAKRABORTY R，JOSHI H, et al.Renal Replacement Therapy in Pediatric Acute Kidney Injury[J].Indian J Pediatr，2020，87(8)：608-617.

贾丽芳，周培一，白文英.慢性肾脏病患者经皮冠脉介入术后急性肾损伤预后及影响因素分析[J].中华肾病研究电子杂志，2021，10(3)：133-137.

龚学忠.从“毒瘀互结”论治造影剂肾病[J].上海中医药杂志，2012，46(2)：57-59.

龚学忠，王跃荣，符丹，等.制大黄－川芎药对对造影剂肾病大鼠肾小管上皮细胞凋亡的影响[J].中国中西医结合肾病杂志，2012，13(8)：675-677.

龚学忠，王骞，符丹，等.制大黄－川芎“药对”抑制造影剂肾病大鼠肾小管上皮细胞凋亡信号通路的机制研究[J].上海中医药杂志，2013，47(3)：69-71.

龚学忠，周令芳，王骞，等.川黄1号方对慢性肾脏病3期患者肾功能及微炎症状态的影响[J].中国中西医结合杂志，2015，35(2)：137-141.

PEERAPORNRATANA S，MANRIQUE-CABALLERO C L，GÓMEZ H, et al.Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment[J].Kidney Int，2019，96(5)：1083-1099.

REN Q，GUO F，TAO S, et al.Flavonoid fisetin alleviates kidney inflammation and apoptosis via inhibiting Src-mediated NF-κB p65 and MAPK signaling pathways in septic AKI mice[J].Biomed Pharmacother，2020，122：109772.

ANDRADE-OLIVEIRA V，FORESTO-NETO O，WATANABE I K, et al.Inflammation in Renal Diseases: New and Old Players[J].Front Pharmacol，2019，10：1192.

CHEN H，FANG Y，WU J, et al.RIPK3-MLKL-mediated necroinflammation contributes to AKI progression to CKD[J].Cell Death Dis，2018，9(9)：878.

BELLIERE J，CASEMAYOU A，COLLIOU E, et al.Ibrutinib does not prevent kidney fibrosis following acute and chronic injury[J].Sci Rep，2021，11(1)：11985.

Views

341

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical efficacy of Chuanhuang Formula in treating patients with chronic kidney disease at stages 3⁃4 and its influence on urinary IL⁃18 and γ⁃GT

Effect of Renal Failure Ⅱ Prescription granule combined with empagliflozin on proteinuria and renal function in patients with CKD at stages 2⁃3

Clinical observation of Shenshuaiyi Formula in treatment of chronic kidney disease at stage 4 combined with chronic heart failure

A prospective clinical study on Yiqi Wenyang Decoction in the treatment of proteinuria in patients with primary CKD at stages 1-2

Effects of Shengjiang Powder on Expression of Toll-like Receptor 4 in Kidney of Rats with Sepsis

Related Author

No data

Related Institution

Department of Nephrology， Shanghai Municipal Hospital of Traditional Chinese Medicine， Shanghai University of Traditional Chinese Medicine

Department of Nephrology， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine； Shanghai Clinical Key Laboratory of Traditional Chinese Medicine； Key Laboratory of Liver and Kidney Diseases， Ministry of Education

Department of Nephrology， the Seventh People’s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Inheritance Studio of Ye Jinghua National Famous Doctor of Traditional Chinese Medicine

Yidan Nursing Home

⁰